ImmunoGen, Inc. Announces Results from Kadcyla® Phase III Trial, TH3RESA, Being Presented Today at the European Cancer Congress

ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, announced the results from Roche’s TH3RESA Phase III trial being presented today at the European Cancer Congress (ECC) in Amsterdam (abstract #LBA15). The findings were accepted as late-breaking data and also included in the Congress’s official press program.

Help employers find you! Check out all the jobs and post your resume.